News Release

One-time gene therapy injection could provide HIV treatment that may last a lifetime

OHSU researcher receives $5 million grant to study long-term suppression of human immunodeficiency virus in nonhuman primates

Grant and Award Announcement

Oregon Health & Science University

Portland, Oregon – A new pre-clinical study in nonhuman primates will evaluate an experimental drug’s potential use as a gene therapy that could prevent people who have HIV from having to take daily antiviral drugs for the rest of their lives.

The research will be led by Oregon Health & Science University researcher Jonah Sacha, Ph.D., who also serves as a scientific advisor to CytoDyn, the biotechnology company developing the drug, called leronlimab. The study is funded by a five-year grant of up to $5 million recently awarded to OHSU by the National Institute of Allergy and Infectious Disease, which is part of the National Institutes of Health. 

“This grant will fund the development and early study of leronlimab as a potential single-injection gene therapy,” said Sacha, a professor at OHSU’s Vaccine and Gene Therapy Institute and Oregon National Primate Research Center. “If this approach works as hoped, it could provide a functional cure for HIV, meaning it could suppress HIV enough that patients would no longer need to take daily antiviral pills for the rest of their lives."

In an earlier study, Sacha and colleagues found leronlimab completely prevented nonhuman primates from being infected with the monkey form of HIV. That result indicated leronlimab held promise as a potential pre-exposure drug to prevent human infection from the virus that causes AIDS. 

Now, this study aims to design a way to offer leronlimab as gene therapy. Sacha and colleagues will explore how to contain the coding sequence of the experimental drug inside a lab-made form of the adeno-associated virus, an approach that gene therapy researchers call an AAV vector. The resulting therapy would then be injected inside the body, where muscle cells would make leronlimab long term.

Leronlimab is a monoclonal antibody that blocks HIV from entering immune cells through a surface protein called CCR5. The drug has demonstrated it can mimic a CCR5-deficient donor by occupying all available CCR5 molecules, but this would require a new method for delivery as a gene therapy. Viral vectors have been used to deliver antigens from specific pathogens for decades.

In this project, researchers will design a synthetic AAV vector to enable the long-term production  leronlimab inside the body. The goal is to develop a safe and effective single injection that suppresses HIV replication and eliminates the need for life-long antiretroviral therapy.

“Currently, patients often take multiple antiretroviral pills daily,” said Sacha. “Removing this pill burden could not only improve patients’ quality of life, but remove problems with adherence.” 

Rhesus macaques at OHSU’s Oregon National Primate Research Center that have been exposed to a monkey version of HIV will be given a single AAV injection that contains leronlimab. Researchers will  monitor the nonhuman primates for years to assess the safety and efficacy of this approach.


This research is supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI166969. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

In our interest of ensuring the integrity of our research and as part of our commitment to public transparency, OHSU actively regulates, tracks and manages relationships that our researchers may hold with entities outside of OHSU. In regards to this research, Dr. Sacha has a significant financial interest in CytoDyn, a company that may have a commercial interest in the results of this research and technology. Review details of OHSU's conflict of interest program to find out more about how we manage these business relationships”

All research involving animal subjects at OHSU must be reviewed and approved by the university’s Institutional Animal Care and Use Committee (IACUC). The IACUC’s priority is to ensure the health and safety of animal research subjects. The IACUC also reviews procedures to ensure the health and safety of the people who work with the animals. No live animal work may be conducted at OHSU without IACUC approval.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.